AstraZeneca plc (LON:AZN) has been assigned a consensus rating of “Hold” from the twenty-two brokerages that are covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and twelve have given a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is GBX 5,170.42 ($68.23).

AZN has been the topic of a number of recent analyst reports. Kepler Capital Markets reissued a “buy” rating and issued a GBX 5,500 ($72.58) price target on shares of AstraZeneca plc in a research report on Thursday, July 13th. Liberum Capital reissued a “buy” rating and issued a GBX 5,500 ($72.58) price target on shares of AstraZeneca plc in a research report on Thursday, July 13th. Citigroup Inc reissued a “buy” rating and issued a GBX 6,000 ($79.18) price target on shares of AstraZeneca plc in a research report on Thursday, July 13th. Deutsche Bank AG reissued a “buy” rating and issued a GBX 5,700 ($75.22) price target on shares of AstraZeneca plc in a research report on Friday, July 28th. Finally, Berenberg Bank set a GBX 5,500 ($72.58) price target on shares of AstraZeneca plc and gave the company a “buy” rating in a research report on Friday, July 28th.

Shares of AstraZeneca plc (LON:AZN) traded up GBX 25 ($0.33) during midday trading on Friday, reaching GBX 5,180 ($68.36). The company’s stock had a trading volume of 1,413,519 shares.

TRADEMARK VIOLATION NOTICE: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.watchlistnews.com/astrazeneca-plc-azn-receives-gbx-5124-90-consensus-price-target-from-analysts/1676818.html.

About AstraZeneca plc

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca plc (LON:AZN)

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with Analyst Ratings Network's FREE daily email newsletter.